Get the Stockscreener App
3.08
11.59%
0.32
Pre-market:
3.23
0.15
+4.87%
Editas Medicine Inc stock is traded at $3.08, with a volume of 9.60M.
It is up +11.59% in the last 24 hours and up +5.84% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
See More
Previous Close:
$2.76
Open:
$2.46
24h Volume:
9.60M
Relative Volume:
5.66
Market Cap:
$301.55M
Revenue:
$40.52M
Net Income/Loss:
$-160.06M
P/E Ratio:
-1.6353
EPS:
-1.8834
Net Cash Flow:
$-165.85M
1W Performance:
+25.20%
1M Performance:
+5.84%
6M Performance:
+28.33%
1Y Performance:
+98.71%
1-Day Range:
$2.41
$3.40
1-Week Range:
$2.41
$3.40
52-Week Range:
$1.5646
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.08 | 270.22M | 40.52M | -160.06M | -165.85M | -1.8834 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Editas Medicine stock dips on proposed equity offering - MSN
Editas Medicine (NASDAQ: EDIT) sells 55.6M shares with warrants to fund EDIT-401 - Stock Titan
Editas Medicine (NASDAQ: EDIT) prices equity deal, extends cash runway to 2H 2028 - Stock Titan
Editas Medicine Prices Public Offering of Shares, Warrants - Moomoo
Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell - Moomoo
H.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Editas Medicine (EDIT) Initiates Public Offering of Common Stock - GuruFocus
EDIT: Financing Efforts Advance with Recent Offering - GuruFocus
Editas Medicine (EDIT) Shares Drop Following Stock Offering Anno - GuruFocus
Editas Medicine prices $125M stock offering with warrants By Investing.com - Investing.com Australia
Editas reports preclinical data for gene editing treatment - Investing.com UK
Editas Medicine prices $125M stock offering with warrants - Investing.com
Editas Medicine stock tumbles on stock offering announcement By Investing.com - Investing.com Nigeria
Editas offering links warrant window to cholesterol trial results - Stock Titan
Editas Medicine stock tumbles on stock offering announcement - Investing.com
Editas Medicine (NASDAQ: EDIT) halts sales under TD Cowen ATM prospectus - Stock Titan
Editas Medicine (EDIT) Showcases Promising Preclinical Findings for EDIT-401 - GuruFocus
Editas reports preclinical data for gene editing treatment By Investing.com - Investing.com Nigeria
Editas Medicine launches public offering of stock and warrants - Investing.com
Editas Medicine (NASDAQ: EDIT) offers common shares, pre-funded warrants and detachable warrants - Stock Titan
EDIT-401 gene-editing data and trial path at Editas Medicine (NASDAQ: EDIT) - Stock Titan
Editas Medicine Announces Proposed Public Offering - Caledonian Record
Gene-editing firm Editas moves to sell new shares and warrants - Stock Titan
Editas Medicine Presents EDIT-401 Preclinical Data Showing ~90% Cuts in LDL-C, Lp(a), and ApoB; CTN Planned Mid-2026 - TradingView
Editas Medicine Announces Promising Preclinical Results for EDIT-401, Showcasing Significant Reductions in LDL-C, Lp(a), and ApoB - Quiver Quantitative
One-shot gene edit slashes multiple cholesterol drivers in animal tests - Stock Titan
Editas Medicine stock (US28106W1036): Recent clinical updates keep investors focused - AD HOC NEWS
Editas Medicine Unveils New Data on EDIT-401 for Hyperlipidemia - Intellectia AI
EDIT's Q1 loss narrower than expected, pipeline in focus - MSN
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT) - Moomoo
JonesTrading Maintains Editas Medicine(EDIT.US) With Buy Rating, Raises Target Price to $8 - Moomoo
EDIT Stock Price, Quote & Chart | EDITAS MEDICINE INC (NASDAQ:EDIT) - ChartMill
Editas Medicine Reports Durable ≥90% LDL-C Reduction With Single Dose of EDIT-401 in Preclinical Hyperlipidemia Data at ASGCT 2026 - Minichart
Editas Medicine stock (US28106W1036): EDIT-401 shows 90% LDL reduction in preclinical study - AD HOC NEWS
Editas Medicine (EDIT) Advances Gene Editing Candidate for Hyper - GuruFocus
Editas Medicine presents preclinical data on EDIT-401 therapy By Investing.com - Investing.com Australia
Editas Medicine presents preclinical data on EDIT-401 therapy - Investing.com UK
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data - TipRanks
EDIT-401 preclinical data show ≥90% LDL-C drop in primates (EDIT) - Stock Titan
Editas Reports ≥90% Mean LDL-C Reduction with Single EDIT-401 Dose in NHPs; Durable ~6 Months - TradingView
Editas Medicine Reports New Preclinical Data Demonstrating - GlobeNewswire
Editas Medicine presents new in vivo gene editing data on EDIT-401 at TIDES USA 2026 Meeting - Traders Union
Editas Medicine unveils cardiovascular research at ASGCT and TIDES USA events - Traders Union
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates - Yahoo Finance
Editas Medicine (NASDAQ:EDIT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Editas Medicine Inc. (EDIT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM) and Editas Medicine (EDIT) - The Globe and Mail
Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):